Evidence map›Paper›PMID 41179671›Full record

ArticleFrontiers in oncology2025

Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case report.

Valentina Di Ruscio, Alessia Carboni, Giada Del Baldo, Maria Debora De Pasquale, Paola Valente, Angela Di Giannatale, Annalisa Serra, Rita De Vito, Angela Mastronuzzi, Concetta Quintarelli and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Retinoblastoma and Its Tumor Microenvironment.Current oncology (Toronto, Ont.) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Valentina Di RuscioDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Alessia CarboniNeuroradiology Unit, "Bambino Gesù" Children's Hospital Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Giada Del BaldoDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Maria Debora De PasqualeDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Paola ValenteOphthalmology Unit, Bambino Gesù Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Children's Hospital, Rome, Italy.
Angela Di GiannataleDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Annalisa SerraDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Rita De VitoPathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Angela MastronuzziDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Concetta QuintarelliDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Biagio De AngelisDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Giuseppe Maria MilanoDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Ida RussoDepartment of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose chemotherapy with autologous stem cell rescue has improved outcomes in patients with metastatic retinoblastoma (RB). However, significant short- and long-term toxicities-especially in very young children with a constitutional

Indexed as

anti-GD2 monoclonal antibodiesextraocularhigh-dose chemotherapyintrathecal topotecanretinolastoma

Identifiers

PMID41179671
PMCPMC12575136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.